Evidence map›Paper›PMID 33063407›Full record

ArticleAngewandte Chemie (International ed. in English)2021

Oleg G Salnikov, Nikita V Chukanov, Alexandra Svyatova, Ivan A Trofimov, Mohammad S H Kabir, Juri G Gelovani, Kirill V Kovtunov, Igor V Koptyug, Eduard Y Chekmenev

Open access · greenAbstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 47 citations in OpenAlex.

  1. The journal of physical chemistry. B · 2025
    Article
  2. SABRE Ir-IMes Catalysis for the Masses.Molecules (Basel, Switzerland) · 2025
    Article
  3. High HThe journal of physical chemistry letters · 2025
    Article
  4. The journal of physical chemistry letters · 2024
    Article
  5. Development of Dissolution Dynamic Nuclear Polarization of [Angewandte Chemie (International ed. in English) · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. EnhancingACS measurement science au · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. RapidAnalytical chemistry · 2022
    Article
  16. Review
  17. Article
  18. Article
  19. Order-UnityChemphyschem : a European journal of chemical physics and physical chemistry · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Oleg G SalnikovBoreskov Institute of Catalysis SB RAS, 5 Acad. Lavrentiev Pr., 630090, Novosibirsk, Russia.ORCID 0000-0003-2266-7335
Nikita V ChukanovInternational Tomography Center SB RAS, 3A Institutskaya St., 630090, Novosibirsk, Russia.ORCID 0000-0003-1246-8869
Alexandra SvyatovaInternational Tomography Center SB RAS, 3A Institutskaya St., 630090, Novosibirsk, Russia.ORCID 0000-0003-3440-6677
Ivan A TrofimovInternational Tomography Center SB RAS, 3A Institutskaya St., 630090, Novosibirsk, Russia.
Mohammad S H KabirDepartment of Chemistry, Integrative Biosciences (Ibio), Karmanos Cancer Institute (KCI), Wayne State University, Detroit, MI, 48202, USA.
Juri G GelovaniDepartment of Chemistry, Integrative Biosciences (Ibio), Karmanos Cancer Institute (KCI), Wayne State University, Detroit, MI, 48202, USA.ORCID 0000-0002-8413-6161
Kirill V KovtunovInternational Tomography Center SB RAS, 3A Institutskaya St., 630090, Novosibirsk, Russia.ORCID 0000-0001-7577-9619
Igor V KoptyugInternational Tomography Center SB RAS, 3A Institutskaya St., 630090, Novosibirsk, Russia.ORCID 0000-0003-3480-7649
Eduard Y ChekmenevDepartment of Chemistry, Integrative Biosciences (Ibio), Karmanos Cancer Institute (KCI), Wayne State University, Detroit, MI, 48202, USA.ORCID 0000-0002-8745-8801
Novosibirsk State University · RUWayne State University · USRussian Academy of Sciences · RU

Funding

Magnetic Resonance Spectroscopy and Molecular Imaging of Metabolic Pathways in CancerR21CA220137 · NCI · WAYNE STATE UNIVERSITY · PI CHEKMENEV, EDUARD · 2017 to 2019
$390k
NCI NIH HHS R21 CA220137
6 · The paper itself

Abstract

Nimorazole belongs to the imidazole-based family of antibiotics to fight against anaerobic bacteria. Moreover, nimorazole is now in Phase 3 clinical trial in Europe for potential use as a hypoxia radiosensitizer for treatment of head and neck cancers. We envision the use of [

Indexed as

Anti-Bacterial AgentsHumansHydrogenMagnetic FieldsMagnetic Resonance SpectroscopyNimorazoleAnti-Bacterial AgentsHydrogenNimorazolehyperpolarizationnimorazoleparahydrogenradiosensitizationSABRE-SHEATH

Identifiers

PMID33063407
PMCPMC7855180
OpenAlexW3092877373

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.